Name (Synonyms) | Correlation | |
---|---|---|
drug2972 | pulmonary ultrasound Wiki | 1.00 |
drug1845 | Placebo injection Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a first-in-human study to assess the safety, tolerability and pharmacokinetics of escalating single doses of apramycin. This trial will be conducted as a single ascending dose trial in up to 5 sequential dose cohorts (group-comparison). Each cohort will consist of 8 healthy subjects, 6 will receive apramycin and 2 placebo.
Description: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant vital sign measurement blood pressure. Time: until 2 weeks after dosingDescription: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant vital sign measurement pulse rate. Time: until 2 weeks after dosingDescription: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant observation in physical examination. Time: until 2 weeks after dosingDescription: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant changes in clinical laboratory parameters. Time: until 2 weeks after dosingDescription: ECG parameters include heart rate and PQ, QT, RS. Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant changes in ECG parameters. Time: until 2 weeks after dosing